This cohort should include comprehensive biomarker collection, including serial measurements of inflammatory cytokines (IL-6, TNF-α, IL-1β), CGRP levels, markers of blood–brain barrier disruption, and genetic polymorphisms that may influence drug metabolism or headache susceptibility. The gene discussed is IL6; the disease is Headache.